Abstract
One hundred and eighteen doctors who treat pulmonary neoplasms in Ontario were asked how they would wish to be treated if they had non-small cell lung cancer. Four different scenarios were given. The physicians were then asked if they would consent to take part as subjects in one or more clinical trials for which they would be eligible in those situations. The proportion of respondents who would consent to each study ranged from 11% to 64%. Reasons given for refusing to participate as subjects in each trial were varied, but many felt that the trials offered unacceptable options for treatment. Medical oncologists consented to each study more frequently than radiation oncologists, respirologists or thoracic surgeons but all disciplines ranked the 6 studies in the same order of acceptability. It is concluded that some patients with non-oat cell lung cancer currently receive experimental therapies with high risk/benefits ratios which experts in the field would not accept for themselves. It is suggested that the expert surrogate system may be useful as an adjunct to the institutional review board in evaluating new trials before they are activated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Mackillop, W., Ward, G. & O'Sullivan, B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer 54, 661–667 (1987). https://doi.org/10.1038/bjc.1986.224
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.224
This article is cited by
-
Use of palliative radiotherapy in brain and bone metastases (VARA II study)
Radiation Oncology (2012)
-
Recruitment for complementary/alternative medicine trials: WHO participates after breast cancer
Annals of Behavioral Medicine (1998)
-
Is there a role for preference assessments in research on quality of life in oncology?
Quality of Life Research (1992)